Generic Dsuvia Availability
Last updated on Apr 10, 2025.
Dsuvia is a brand name of sufentanil, approved by the FDA in the following formulation(s):
DSUVIA (sufentanil citrate - tablet;sublingual)
-
Manufacturer: VERTICAL PHARMS
Approval date: November 2, 2018
Strength(s): EQ 0.03MG BASE (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dsuvia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Patent 10,245,228
Issued: April 2, 2019
Inventor(s): Palmer Pamela & Schreck Thomas & Tzannis Stelios & Hamel Larry & Poutiatine Andrew I.
Assignee(s): AcelRx Pharmaceuticals, Inc.Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.
Patent expiration dates:
- January 5, 2027✓✓
- January 5, 2027
-
Small-volume oral transmucosal dosage forms
Patent 10,342,762
Issued: July 9, 2019
Inventor(s): Palmer Pamela & Schreck Thomas & Tzannis Stelios & Hamel Lawrence & Poutiatine Andrew I.
Assignee(s): AcelRx Pharmaceuticals, Inc.Small-volume oral transmucosal dosage forms or NanoTabs® comprising a predetermined amount of a pharmaceutically active drug are provided. Exemplary applications include use of the NanoTabs® to administer a drug for the treatment of acute, post-operative or breakthrough pain.
Patent expiration dates:
- January 5, 2027✓
- January 5, 2027
-
Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Patent 10,507,180
Issued: December 17, 2019
Inventor(s): Palmer Pamela & Schreck Thomas & Tzannis Stelios & Hamel Larry & Poutiatine Andrew I.
Assignee(s): AcelRx Pharmaceuticals, Inc.Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.
Patent expiration dates:
- January 5, 2027✓✓
- January 5, 2027
-
Storage and dispensing devices for administration of oral transmucosal dosage forms
Patent 10,896,751
Issued: January 19, 2021
Inventor(s): Poutiatine Andrew & Edwards Bruce & Rampersaud Charles & Palmer Pamela & Blackwood Bradley & Yaffe Benjamin K.
Assignee(s): AcelRx Pharmaceuticals, Inc.Dispensing devices and systems for oral transmucosal administration of small volume drug dosage forms to the oral mucosa are provided. The dispensing device may be a single dose applicator (SDA), or an electromechanical device comprising a means for patient identification such as a wrist worn RFID tag and annular bidirectional antenna together with a lock-out feature.
Patent expiration dates:
- March 16, 2030✓
- March 16, 2030
-
Apparatus and methods for dispensing oral transmucosal dosage forms
Patent 11,672,738
Issued: June 13, 2023
Inventor(s): Domingo; Casidy et al.
Assignee(s): Vertical Pharmaceuticals, LLC (Alpharetta, GA)Single dose drug dosage form dispensing devices, and methods for operating such devices are disclosed herein. In one embodiment, an apparatus includes a housing defining an actuation pathway and a pusher. At least a portion of the pusher is disposed within the actuation pathway such that distal end portions of the pusher and the housing define a volume configured to contain a drug-containing tablet. The pusher is configured to move relative to the housing in a distal direction from a first position to a second position to expel the tablet from the volume. The distal end portion of the pusher is extended from an opening in the housing when the pusher is in its second position. The housing is configured to limit movement of the pusher relative to the housing in a proximal direction towards the first position of the pusher after the tablet is expelled.
Patent expiration dates:
- February 2, 2038✓
- February 2, 2038
-
Storage and dispensing devices for administration of oral transmucosal dosage forms
Patent 11,676,691
Issued: June 13, 2023
Inventor(s): Poutiatine; Andrew et al.
Assignee(s): Vertical Pharmaceuticals, LLC (Alpharetta, GA)Dispensing devices and systems for oral transmucosal administration of small volume drug dosage forms to the oral mucosa are provided. The dispensing device may be a single dose applicator (SDA), or an electromechanical device comprising a means for patient identification such as a wrist worn RFID tag and annular bidirectional antenna together with a lock-out feature.
Patent expiration dates:
- March 16, 2030✓
- March 16, 2030
-
Storage and dispensing devices for administration of oral transmucosal dosage forms
Patent 12,033,733
Issued: July 9, 2024
Inventor(s): Poutiatine; Andrew et al.
Assignee(s): Vertical Pharmaceuticals, LLC (Alpharetta, GA)Dispensing devices and systems for oral transmucosal administration of small volume drug dosage forms to the oral mucosa are provided. The dispensing device may be a single dose applicator (SDA), or an electromechanical device comprising a means for patient identification such as a wrist worn RFID tag and annular bidirectional antenna together with a lock-out feature.
Patent expiration dates:
- March 16, 2030✓
- March 16, 2030
-
Small-volume oral transmucosal dosage forms
Patent 8,202,535
Issued: June 19, 2012
Inventor(s): Palmer Pamela & Schreck Thomas & Tzannis Stelios & Hamel Larry & Poutiatine Andrew I.
Assignee(s): Acelrx Pharmaceuticals, Inc.Small-volume oral transmucosal dosage forms or NanoTabs® comprising a predetermined amount of a pharmaceutically active drug are provided. Exemplary applications include use of the NanoTabs® to administer a drug for the treatment of acute, post-operative or breakthrough pain.
Patent expiration dates:
- October 22, 2030✓
- October 22, 2030
-
Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Patent 8,226,978
Issued: July 24, 2012
Inventor(s): Palmer Pamela & Schreck Thomas & Tzannis Stelios & Hamel Larry & Poutiatine Andrew I. & Rampersaud Charles & Edwards Bruce
Assignee(s): AcelRx Pharmaceuticals, Inc.Compositions, methods and systems for administration of small volume sufentanil-containing drug dosage forms to the oral mucosa of a subject are disclosed.
Patent expiration dates:
- January 5, 2027✓✓
- January 5, 2027
-
Small-volume oral transmucosal dosage
Patent 8,231,900
Issued: July 31, 2012
Inventor(s): Palmer Pamela & Schreck Thomas & Tzannis Stelios & Hamel Larry & Poutiatine Andrew I.
Assignee(s): Acelrx Pharmaceutical, Inc.Small-volume oral transmucosal dosage forms or NanoTabs® comprising a predetermined amount of a pharmaceutically active drug are provided. Exemplary applications include use of the NanoTabs® to administer a drug for the treatment of acute, post-operative or breakthrough pain.
Patent expiration dates:
- January 5, 2027✓
- January 5, 2027
-
Bioadhesive drug formulations for oral transmucosal delivery
Patent 8,252,328
Issued: August 28, 2012
Inventor(s): Tzannis Stelios & Palmer Pamela & Schreck Thomas & Hamel Larry & Poutiatine Andrew I.
Assignee(s): Acelrx Pharmaceuticals, Inc.Formulations for controlled delivery of oral transmucosal medications are provided. The formulations are characterized as hydrogel-forming or eroding-types which are bioadhesive and provide for controlled and sustained release of the medication such that enhanced bioavailability and efficacy is provided.
Patent expiration dates:
- January 5, 2027✓
- January 5, 2027
-
Bioadhesive drug formulations for oral transmucosal delivery
Patent 8,252,329
Issued: August 28, 2012
Inventor(s): Tzannis Stelios & Hamel Larry & Palmer Pamela & Schreck Thomas & Poutiatine Andrew I.
Assignee(s): Acelrx Pharmaceuticals, Inc.Bioadhesive drug formulations that adhere to an oral mucosal membrane of a subject are provided together with single dose applicators and devices for delivering the drug formulations to the oral mucosa, and methods for using the same.
Patent expiration dates:
- January 5, 2027✓
- January 5, 2027
-
Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Patent 8,535,714
Issued: September 17, 2013
Inventor(s): Palmer Pamela & Schreck Thomas & Hamel Lawrence & Tzannis Stelio & Poutiatine Andrew
Assignee(s): AcelRx Pharmaceuticals, Inc.Compositions, systems and methods for administration of small volume sufentanil drug dosage forms via the oral transmucosal route of a subject for treatment of pain.
Patent expiration dates:
- January 5, 2027✓✓
- January 5, 2027
-
Storage and dispensing devices for administration of oral transmucosal dosage forms
Patent 8,574,189
Issued: November 5, 2013
Inventor(s): Poutiatine Andrew & Edwards Bruce & Rampersaud Charles & Palmer Pamela & Blackwood Bradley & Yaffe Benjamin K.
Assignee(s): AcelRx Pharmaceuticals, Inc.Dispensing devices and systems for oral transmucosal administration of small volume drug dosage forms to the oral mucosa are provided. The dispensing device may be a single dose applicator (SDA), or an electromechanical device comprising a means for patient identification such as a wrist worn RFID tag and annular bidirectional antenna together with a lock-out feature.
Patent expiration dates:
- March 16, 2030✓
- March 16, 2030
-
Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Patent 8,778,393
Issued: July 15, 2014
Inventor(s): Palmer Pamela & Schreck Thomas & Tzannis Stelios & Hamel Larry & Poutiatine Andrew I. & Rampersaud Charles & Edwards Bruce
Assignee(s): AcelRx Pharmaceuticals, Inc.Compositions, methods and systems for administration of small volume sufentanil-containing drug dosage forms to the oral mucosa of a subject are disclosed.
Patent expiration dates:
- January 5, 2027✓
- January 5, 2027
-
Small-volume oral transmucosal dosage forms
Patent 8,778,394
Issued: July 15, 2014
Inventor(s): Palmer Pamela & Schreck Thomas & Tzannis Stelios & Hamel Larry & Poutiatine Andrew I.
Assignee(s): AcelRx Pharmaceuticals, Inc.Small-volume oral transmucosal dosage forms or NanoTabs® comprising a predetermined amount of a pharmaceutically active drug are provided. Exemplary applications include use of the NanoTabs® to administer a drug for the treatment of acute, post-operative or breakthrough pain.
Patent expiration dates:
- January 5, 2027✓
- January 5, 2027
-
Bioadhesive drug formulations for oral transmucosal delivery
Patent 8,865,211
Issued: October 21, 2014
Inventor(s): Tzannis Stelios & Hamel Larry & Palmer Pamela & Schreck Thomas & Poutiatine Andrew I.
Assignee(s): AcelRx Pharmaceuticals, Inc.Bioadhesive drug formulations that adhere to an oral mucosal membrane of a subject are provided together with single dose applicators and devices for delivering the drug formulations to the oral mucosa, and methods for using the same.
Patent expiration dates:
- January 5, 2027✓
- January 5, 2027
-
Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Patent 8,865,743
Issued: October 21, 2014
Inventor(s): Palmer Pamela & Schreck Thomas & Tzannis Stelios & Hamel Larry & Poutiatine Andrew I. & Rampersaud Charles & Edwards Bruce
Assignee(s): AcelRx Pharmaceuticals, Inc.Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.
Patent expiration dates:
- October 22, 2030✓
- October 22, 2030
-
Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
Patent 8,945,592
Issued: February 3, 2015
Inventor(s): Pushpala Shamim & Hamel Larry & Tzannis Stelios & Cruz Evangeline
Assignee(s): AcelRx Pharmaceuticals, Inc.Compositions and methods effective to minimize or eliminate the presence of oxidative degradation products in solid dosage forms comprising sufentanil are provided.
Patent expiration dates:
- July 29, 2031✓
- July 29, 2031
-
Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Patent 9,320,710
Issued: April 26, 2016
Inventor(s): Palmer Pamela & Schreck Thomas & Tzannis Stelios & Hamel Larry & Poutiatine Andrew I.
Assignee(s): AcelRX Pharmaceuticals, Inc.Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.
Patent expiration dates:
- January 5, 2027✓
- January 5, 2027
-
Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Patent 9,744,129
Issued: August 29, 2017
Inventor(s): Palmer Pamela & Schreck Thomas & Tzannis Stelios & Hamel Larry & Poutiatine Andrew I.
Assignee(s): AcelRx Pharmaceuticals, Inc.Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.
Patent expiration dates:
- January 5, 2027✓
- January 5, 2027
More about Dsuvia (sufentanil)
- Dsuvia consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: Opioids (narcotic analgesics)
- Breastfeeding
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.